Antibody-based target identification reveals AZD-9291 repressing cancer cells via down-regulation of ribonucleotide reductase
碩士 === 國立臺灣大學 === 生化科學研究所 === 105 === AZD-9291(Osimertinib, TagrissoTM) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that has been developed by AstraZeneca for the treatment of advanced non-small cell lung cancer (NSCLC). AZD-9291 has been design...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2017
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/q5rb9a |